News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Entry into a Material Definitive Agreement.
On Nov 30, 2023 (the “Effective Date”), the Company and Undo Studios SA, (Nemesis) entered into a Sales Purchase agreement, to acquire 31% of the share capital of Nemesis in a share swap and cash transaction representing a minority interest in the assets, licenses, and intellectual property of Nemesis.
Pursuant to the provisions in the Sale Purchase Agreement, the Company will issue (six million six hundred and fifty thousand) 6,650,000 shares of its common stock at fair market value as of the date of the Sale Purchase Agreement for the initial 20% and the option for the remaining 11% of Nemesis. The common shares issued for the conversion if exercised, shall be issued with a restriction under Rule 144 of the U.S. Securities and Exchange Commission Act of 1934. That portion of the Company’s issued shares representing the 11% of the Nemesis acquisition will be held in escrow until such time as the option has been exercised.
In addition, the Company agrees to invest a total amount of (one million two hundred thousand) $1,200,000 in cash installments of (one hundred thousand) $ 100,000 per month starting December 1, 2023. Any amounts previously paid to Nemesis under a previously reported Letter of Intent will be deducted from this amount due.
The Company has the option to acquire an additional 11% of Nemesis upon fulfillment of certain milestones to be agreed upon in a future agreement. Nemesis will provide one seat to Arax as a Director of Undo Studios and will allow Arax to have operational oversight on an ongoing basis.
With this big news coming you will see 8.00-14.00 within 20 days imo. Mark it. Then continuous updates will keep it in this price range.
Hoping to see NITE & CSTI move the bid higher
Highest bid
Very nice OTCN no longer around, I’m hoping to see INTL on the top bid soon
Move along OTCN
Yah I totally get it, the problem is they did not have anything to pump, now we are live let’s see what he has in store for us pr wise.
💲The PriceFeed CIP introduces the "PriceFeed" contract, which is crafted to function as a decentralized oracle responsible for aggregating and supplying asset price data.
Make sure to find out more here:↘️
https://cip.coreblockchain.net/cip/cbc/cip-104
✅CIP-712, the Core Signature Verification Standard, establishes a set of guidelines for the secure encoding and verification of structured data signatures within applications built on the Core Blockchain.
Read more in our CIP article.↘️
https://cip.coreblockchain.net/cip/cbc/cip-712
That’s for sure! It was also nice to see INTL at 1.02. INTL also move there ask to 1.85
Past video's they will be uplisting to Nasdaq 2024 imo.
Need CSTI to move above a 1.10
So true, I believe there is a plan to let the world know what we own here.
You don’t spend 9 plus years in development and close to 30 million dollars to let this die
Let’s see what they pr next month
Hoping to see there pr campaign roll out!
Also would love to see client list.
Plus looking forward to the 10q. Hoping for 20% increase in revenues
We are excited to confirm that Core Token was officially deployed on the Core Blockchain network at 17:23 UTC on November 17th 2023, marking its existence as a tangible and ready-to-distribute asset. This momentous occasion can be witnessed on blockindex.net, the official block explorer for Core Blockchain. This deployment demonstrates the tangible value of Core Token and showcases the capabilities and potential of the newly established CBC20 Standard.
|
Followers
|
39
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
5843
|
|
Created
|
01/08/14
|
Type
|
Free
|
| Moderators splintered sunlight | |||
Case A-20-825346-B in the
Eighth Judicial District Court Portal
https://www.clarkcountycourts.us/Portal/
11/24/2020
Motion for Appointment of Custodian
12/30/2020
Order 201230 - ARAX Order Appointing Custodian
Parties Present 9:30 AM: Chasey, Peter L. - Attorney (Lazar's Attorney)
Minutes: All appearances made via the BlueJeans Videoconferencing Application. Colloquy regarding typographical error in pleadings that changed "ARAX" to "ARAT". Court stated its findings and ORDERED, Motion for Appointment of Custodian GRANTED. Mr. Chasey to prepare the order and clarify the typographical error.1/11/2021
Motion for Order
Motion to Require Written Proofs of Claim
01/12/2021
Clerk's Notice of Hearing
Clerks Notice of Hearing
01/13/2021
Certificate of Service
Certificate of Service
02/18/2021
Motion (9:30 AM) (Judicial Officer Allf, Nancy)
Motion to Require Written Proofs of Claim
There being no opposition, Motion Granted
03/23/2021
Affidavit of Publication
Filed by Scott Sibley, Publisher of Nevada Legal News
03/31/2021
Motion for Order
Motion to Bar Unasserted Claims and Terminate Custodianship
03/31/2021
Clerk's Notice of Hearing
"Please be advised that the Motion to Bar Unasserted Claims and Terminate above-entitled matter is set for hearing as follows
Date: May 5, 2021
Time: 9:00 AM"
Location: RJC Courtroom ...."04/20/2021
Status CheckJudicial Officer
Allf, NancyHearing Time
3:00 AMComment
wirtten proofs of claiim (that is how the clerk wrote that sentence)
Journal Entry
"Court further finds after review that on March 31, 2021 a motion to bar unasserted claims and Terminate Custodianship was filed. The motion stated that the Custodian served Notice of Entry of Order via publication, which was completed on March 23, 2021. The Motion also stated that no proofs of claim have been filed or otherwise submitted to the Custodian."
05/05/2021
MotionJudicial Officer
Allf, NancyHearing Time
9:00 AMComment
Motion to Bar Unasserted Claims and Terminate Custodianship
05/05/2021 Order
Order barring unasserted claims and terminating custodianship.
“Pursuant to a revision to a certain Consulting Agreement dated October 8, 2013, between Thru Pharma and Strategic Universal Advisors, LLC (“Strategic”), as amended effective January 17, 2014, on or about February 9, 2015, and most recently on October 20, 2015, with full effect as of April 1, 2015 (the “Consulting Agreement”), Thru Pharma and Strategic agreed that the intent of the Consulting Agreement ab initio was to provide Strategic with a 3% equity ownership of Thru Pharma in the event that a PUBCO M&A transaction did not occur prior to the end of the Consulting Agreement. Thru Pharma and Strategic agreed and stipulated that 753,504 shares of the Company would equal 3% of Thru Pharma as the equity payment under the Consulting Agreement, with transfer subject to the further provisions stated below. As Thru Pharma was the sole beneficiary of the services provided by Strategic under the Consulting Agreement, no part of the value of the consideration for services provided under the Consulting Agreement has been recognized as an expense by the Company.
In connection with earlier amendments to the Consulting Agreement, Strategic granted to Mr. Keough, a control person of the Company and Thru Pharma, an irrevocable proxy (the “Irrevocable Proxy”), to vote all of the common stock in the Company under certain conditions. That proxy no longer exists under the terms of the most recent amendment.
As part of the currently amended Consulting Agreement, Thru Pharma agreed to transfer 753,504 Company shares to Strategic upon the closing of a merger or acquisition (an “M&A Transaction”) of a public entity, resulting in Thru Pharma being the controlling owner of the entity that was the subject of the M&A Transaction, and Thru Pharma would cause such entity to also issue to Strategic a stock warrant to purchase 600,000 (six hundred thousand) shares of common stock of the entity that was the subject of the M&A Transaction. Such warrant will be of five-year duration, exercisable at $0.10 per share, and shall vest in four equal amounts of 150,000 shares with the first annual vesting to occur 60 (sixty) days following the completion of the PUBCO M&A Transaction, as well as other routine terms.”
“Effective July 1, 2015, Arax and Catalyst Funding, LLC, entered into an Original Issue Discount Revolving Secured Convertible Promissory Note (the “Catalyst Note”) and a Securities Purchase Agreement (the “Catalyst SPA”). The transaction is secured by a grant of security interest to 100% of the Company stock held by or for Thru Pharma. The Catalyst Note and Catalyst SPA are intended to facilitate funding essential work relating to reporting and accounting costs. The total available funds are $200,000, and the Company has only drawn $75,000, and for which the Company is obligor. A Commitment Fee of Company stock in the amount of 35,294 shares was authorized for issue to Catalyst as part of the transaction recorded as an initial debt discount of $14,118. In the event that the Company is unable to timely make payments under this Agreement, Catalyst has the option of gaining control of the Thru Pharma shares in the Company.
On March 1, 2017, the Company’s majority shareholder, Thru Pharma LLC entered into a merger agreement with Kasten, Inc., a Nevada corporation (“Kasten”), whereby Kasten was the surviving corporation. As part of the merger agreement, the shares in the Company held by Thru Pharma were withheld from the agreement and the Company was no longer identified as a subsidiary of Thru Pharma thereby effectively spinning out the Company and excluding it from the surviving entity. Kasten has been identified as party to and co-guarantor of the Catalyst note. The Company is in the process of settling the note with Catalyst whereby funds used to satisfy the note are being provided by its Chief Executive Officer, Steven J. Keough whereas Mr. Keough will be effectively purchasing the 8,000,000 common shares in the Company and the Arax Holdings Corp receivable (listed on the books of the Company as a related party payable in the amount of $211,149 for the nine months ended July 31, 2016) in exchange for extinguishing the note. The 8,000,000 shares are currently collateralizing the Catalyst loan. Upon satisfaction of the note, the Company’s related party payable will be due to Mr. Keough, and he will become the majority shareholder in the Company.
--------------------------End Hug Life Section
AI
